Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing

Experimental Hematology and Oncology

Volumn 4, Issue 1, 2015, Pages

  Mandelker, Diana ^a   Cin, Paola ^a   Jacene, Heather A ^b   Armand, Philippe ^b   Stone, Richard M ^b   Lindeman, Neal I ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

FIP1L1 PDGFRA; Myeloid sarcoma; Next generation sequencing; Somatic sequencing

Indexed keywords

CLOFARABINE; CYTARABINE; DAUNORUBICIN; DECITABINE; IMATINIB;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESISTANCE; CASE REPORT; CYTOGENETICS; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FIP1L1 PDGFRA GENE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FUSION GENE; GENE REARRANGEMENT; GRAFT VERSUS HOST REACTION; GRANULOCYTIC SARCOMA; HIGH THROUGHPUT SEQUENCING; HUMAN; LEUKOCYTE COUNT; LYMPH NODE BIOPSY; MALE; PANCYTOPENIA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; TRISOMY 8;

EID: 84978023498     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/s40164-015-0026-x     Document Type: Article

References (16)

1. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-19. doi: 10.1056/NEJMoa1002011.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-32. doi: 10.1056/NEJMoa050753.
3. Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, et al. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist. 2014;19(6):616-22. doi: 10.1634/theoncologist.2014-0011.
4. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010;2(5):146-58. doi: 10.1002/emmm.201000070.
5. Doyle LA, Wong KK, Bueno R, Dal Cin P, Fletcher JA, Sholl LM, et al. Ewing sarcoma mimicking atypical carcinoid tumor: detection of unexpected genomic alterations demonstrates the use of next generation sequencing as a diagnostic tool. Cancer Genet. 2014;207(7-8):335-9. doi: 10.1016/j.cancergen.2014.08.004.
6. Abo RP, Ducar M, Garcia EP, Thorner AR, Rojas-Rudilla V, Lin L, et al. BreaKmer: detection of structural variation in targeted massively parallel sequencing data using kmers. Nucleic Acids Res. 2014. doi: 10.1093/nar/gku1211.
7. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-14. doi: 10.1056/NEJMoa025217.
8. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51. doi: 10.1182/blood-2009-03-209262.
9. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA. 2003;100(13):7830-5. doi: 10.1073/pnas.0932698100.
10. Stover EH, Chen J, Folens C, Lee BH, Mentens N, Marynen P, et al. Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independent. Proc Natl Acad Sci USA. 2006;103(21):8078-83. doi: 10.1073/pnas.0601192103.
11. Tang TC, Chang H, Chuang WY. Complete response of myeloid sarcoma with FIP1L1-PDGFRA -associated myeloproliferative neoplasms to imatinib mesylate monotherapy. Acta Haematol. 2012;128(2):83-7. doi: 10.1159/000338217.
12. Shah S, Loghavi S, Garcia-Manero G, Khoury JD. Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. J Hematol Oncol. 2014;7:26. doi: 10.1186/1756-8722-7-26.
13. Chen D, Bachanova V, Ketterling RP, Begna KH, Hanson CA, Viswanatha DS. A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease. Am J Surg Pathol. 2013;37(1):147-51. doi: 10.1097/PAS.0b013e31826df00b.
14. Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, et al. Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007;21(6):1183-8. doi: 10.1038/sj.leu.2404662.
15. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70. doi: 10.1186/s13045-014-0070-8.
16. Subbiah V, McMahon C, Patel S, Zinner R, Silva EG, Elvin JA, et al. STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. J Hematol Oncol. 2015;8:66. doi: 10.1186/s13045-015-0160-2.